Pharmacyclics, Inc. (PCYC) Reports First Quarter 2013 Results
5/2/2013 6:40:45 AM
More...
|
Pharmacyclics, Inc. (PCYC) Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
4/25/2013 6:50:07 AM
More...
|
Pharmacyclics, Inc. (PCYC) Completes Enrollment of First Phase III Ibrutinib CLL Study - RESONATE™ and Announces Completion of Enrollment of Phase II Ibrutinib MCL Study - SPARK
4/19/2013 9:04:00 AM
More...
|
Pharmacyclics, Inc. (PCYC) Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
4/11/2013 9:55:43 AM
More...
|
Pharmacyclics, Inc. (PCYC) Release: Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
4/8/2013 11:40:28 AM
More...
|
Pharmacyclics, Inc. (PCYC) Announces Third Breakthrough Therapy Designation for Ibrutinib from the FDA
4/8/2013 10:06:30 AM
More...
|
Johnson & Johnson (JNJ), Pharmacyclics, Inc. (PCYC) Gets New Breakthrough-Therapy Designation for Ibrutinib
4/8/2013 8:05:27 AM
More...
|
Pharmacyclics, Inc. (PCYC) Prices Public Offering of Common Stock
3/8/2013 9:57:37 AM
More...
|
Pharmacyclics, Inc. (PCYC) Announces Proposed Public Offering of Common Stock
3/8/2013 9:26:33 AM
More...
|
Abbott Molecular, Inc. Forms Pact With Janssen Biotech Inc. for Leukemia Test
2/21/2013 7:28:03 AM
More...
|
|